Nicholas DeVito Highlights Enrollment for BBOpCo Immunotherapy Trial
Nicholas DeVito, Assistant Professor at Duke Cancer Institute, shared the following insightful post on LinkedIn:
“Our first-line immunotherapy (botensilimab/balstilimab) trial for advanced/metastatic colorectal cancer without liver, bone, or brain metastasis is still enrolling!
This trial is supported by Gateway for Cancer Research, Duke CRUSH CRC, and patient philanthropy.
Learn more about the BBOpCo trial here.”
This post by Nicholas DeVito highlights the ongoing recruitment for the BBOpCo trial, a first-line immunotherapy study for patients with advanced or metastatic colorectal cancer, excluding those with liver, bone, or brain metastases. The trial, supported by Gateway for Cancer Research, Duke CRUSH CRC, and patient philanthropy, is advancing the field of colorectal cancer treatment by evaluating the combination of botensilimab and balstilimab. Dr. DeVito emphasizes the trial’s significance in offering new immunotherapeutic options for this patient population.
More posts featuring Nicholas DeVito on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023